About

About CuraTeQ Biologics (a wholly owned subsidiary of Aurobindo Pharma Ltd.) is an biopharmaceutical company headquartered in Hyderabad, India. Our vision is to improve the wellbeing of patients suffering from debilitating illnesses by providing them access to high quality and cost-effective biosimilars. CuraTeQ has a development pipeline of 14 biosimilars with a focus on oncology and immunology, of which, three products have been filed with EMA, one product has been filed with MHRA, and four more products are in global phase 3 clinical trials. - ®, (Bevacizumab biosimilar), has received MHRA approval. - ®, (Pegfilgrastim biosimilar), has received EMA approval. - ®, (Filgrastim biosimilar), has received EMA approval. - ®, (Trastuzumab biosimilar), has received CHMP positive opinion, and CDSCO approval in India. : - , our synthetic peptide API manufacturing arm is a US FDA certified facility. We have filed 14 DMFs with the US FDA, contributing to 6 ANDA approvals and 2 CEP approvals. - : we offer a wide spectrum of CDMO services across biologics, peptides, and oligonucleotides including sterile drug product contract manufacturing at our affiliate . 𝗖𝘂𝗿𝗮𝗧𝗲𝗤 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 (a wholly owned subsidiary of Aurobindo Pharma Ltd.) is an 𝗘𝗨 𝗚𝗠𝗣 𝗰𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 biopharmaceutical company headquartered in Hyderabad, India. Our vision is to improve the wellbeing of patients suffering from debilitating illnesses by providing them access to high quality and cost-effective biosimilars. CuraTeQ has a development pipeline of 14 biosimilars with a focus on oncology and immunology, of which, three products have been filed with EMA, one product has been filed with MHRA, and four more products are in global phase 3 clinical trials. - 𝗕𝗲𝘃𝗾𝗼𝗹𝘃𝗮®, (Bevacizumab biosimilar), has received MHRA approval. - 𝗗𝘆𝗿𝘂𝗽𝗲𝗴®, (Pegfilgrastim biosimilar), has received EMA approval. - 𝗭𝗲𝗳𝘆𝗹𝘁𝗶®, (Filgrastim biosimilar), has received EMA approval. - 𝗗𝗮𝘇𝘂𝗯𝗹𝘆𝘀®, (Trastuzumab biosimilar), has received CHMP positive opinion, and CDSCO approval in India. 𝗢𝘂𝗿 𝗔𝗳𝗳𝗶𝗹𝗶𝗮𝘁𝗲𝘀 𝗮𝗻𝗱 𝗦𝗲𝗿𝘃𝗶𝗰𝗲 𝗼𝗳𝗳𝗲𝗿𝗶𝗻𝗴𝘀: - 𝗔𝘂𝗿𝗼 𝗣𝗲𝗽𝘁𝗶𝗱𝗲𝘀, our synthetic peptide API manufacturing arm is a US FDA certified facility. We have filed 14 DMFs with the US FDA, contributing to 6 ANDA approvals and 2 CEP approvals. - 𝗖𝗗𝗠𝗢 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀: we offer a wide spectrum of CDMO services across biologics, peptides, and oligonucleotides including sterile drug product contract manufacturing at our affiliate 𝗔𝘂𝗿𝗼 𝗩𝗮𝗰𝗰𝗶𝗻𝗲𝘀.